Cristin-resultat-ID: 2008290
Sist endret: 8. februar 2023, 11:02
NVI-rapporteringsår: 2022
Resultat
Vitenskapelig artikkel
2022

Autoimmune Thyroid Disorders in Autoimmune Addison Disease

Bidragsytere:
  • Ann-Elin Meling Stokland
  • Grethe Åstrøm Ueland
  • Kari Lima
  • Kaja Grønning
  • Trine Elisabeth Finnes
  • Margrethe Svendsen
  • mfl.

Tidsskrift

Journal of Clinical Endocrinology and Metabolism (JCEM)
ISSN 0021-972X
e-ISSN 1945-7197
NVI-nivå 2

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2022
Publisert online: 2022
Trykket: 2022
Volum: 107
Hefte: 6
Sider: e2331 - e2338
Open Access

Importkilder

Scopus-ID: 2-s2.0-85130136878

Beskrivelse Beskrivelse

Tittel

Autoimmune Thyroid Disorders in Autoimmune Addison Disease

Sammendrag

Context: Autoimmune thyroid disease is the most common endocrine co-morbidity in autoimmune Addison's disease (AAD), but detailed investigations of prevalence and clinical course is lacking. Objective: Provide comprehensive epidemiological and clinical data on autoimmune thyroid disorders in AAD. Design and patients: A nationwide registry-based study including 442 patients with AAD and autoimmune thyroid disease, identified through the Norwegian National Registry of Autoimmune Diseases. Results: Of 912 registered AAD patients, 442 (48%) were diagnosed with autoimmune thyroid disease. Three hundred and eighty (42%) had autoimmune hypothyroidism. Of the 302 with available thyroid function tests at time for diagnosis, 20% had overt hypothyroidism, 73% had subclinical hypothyroidism and 7% had thyroid levels in the normal range. Negative thyroid peroxidase antibodies was found in 32%. Ninety-eight percent were treated with levothyroxine, 5% with combination therapy with liothyronine or thyroid extracts, and 1% were observed without treatment. Seventy-eight patients (9%) were diagnosed with Graves' disease (GD), of whom 16 (21%) were diagnosed with autoimmune hypothyroidism either before onset or after remission of GD. At the end of follow-up 33% had normal thyroid hormone levels without antithyroid-drugs or levothyroxine treatment. The remaining had either active disease (5%), had undergone ablative treatment (41%), or had developed autoimmune hypothyroidism (21%). Conclusion: The true prevalence of hypothyroidism in AAD is lower than reported in current literature. Careful consideration of the indication to start thyroxin therapy is warranted. Long-term remission rates in GD patients with AAD are comparable to recent reports on long-term follow-up of patients without AAD.

Bidragsytere

Ann-Elin Meling Stokland

  • Tilknyttet:
    Forfatter
    ved Mottaksklinikken ved Helse Stavanger HF - Stavanger universitetssjukehus

Grethe Åstrøm Ueland

  • Tilknyttet:
    Forfatter
    ved Medisinsk klinikk ved Helse Bergen HF - Haukeland universitetssykehus

Kari Lima

  • Tilknyttet:
    Forfatter
    ved Endokrinologi ved Akershus universitetssykehus HF

Kaja Grønning

  • Tilknyttet:
    Forfatter
    ved Medisinsk divisjon ved Akershus universitetssykehus HF

Trine Elisabeth Finnes

  • Tilknyttet:
    Forfatter
    ved Spesialisert endokrinologi, seksjon for ved Oslo universitetssykehus HF
  • Tilknyttet:
    Forfatter
    ved Div Elverum-Hamar ved Sykehuset Innlandet HF
1 - 5 av 22 | Neste | Siste »